Boston Scientific names Fitzgerald COO and Boston Scientific stock costs EUR 37.72

Published on 10/09/2026 at 15:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Three segments begin January 1, 2027 under the new COO. Boston Scientific stock costs EUR 37.72 on October 9, 2026 after EUR 37.47, plus 0.67 percent.

Key points in brief

Boston Scientific appointed Joseph M. Fitzgerald chief operating officer effective January 1, 2027, alongside a three-segment structure.
Second-quarter 2026 revenue reached USD 5.44 billion, up 7.50 percent year over year, while adjusted earnings per share reached USD 0.86.
The stock was trading at EUR 37.72 at Lang & Schwarz on October 9, 2026, up 0.67 percent from EUR 37.47.

Makro-Nahaufnahme einer Glasvorhangfassade mit Aluminium-Pfosten-Riegel-Konstruktion und Wolkenreflexion — Boston Properties US1011371077 zeigt eine extreme Makro-Detailaufnahme einer Glasvorhangfassade mit präzisen Aluminiumrahmen, Illustration mit AI erstellt.

Boston Scientific (ISIN US1011371077) was trading at EUR 37.72 at Lang & Schwarz on October 9, 2026 at 3:43 p.m. CEST, up 0.67 percent from the EUR 37.47 prior close of October 8, 2026. On October 7, 2026, Boston Scientific appointed Joseph M. Fitzgerald executive vice president and chief operating officer, effective January 1, 2027.

Three dates show the reset

On July 29, 2026, Boston Scientific reported second-quarter revenue of USD 5.44 billion and adjusted earnings per share of USD 0.86, compared with USD 0.75 a year earlier, according to MarketBeat. On September 17, 2026, Citigroup lowered its price target from USD 57.00 to USD 50.00 while changing its rating from Buy to Neutral, as MarketScreener reported. On October 5, 2026, Citigroup cut the target again from USD 50.00 to USD 48.00 and kept Neutral, according to MarketBeat.

What does the new structure change?

The January 1, 2027 reorganization will create three reportable segments: Interventional Therapies, Rhythm Solutions and MedSurg. Fitzgerald will oversee global operations, business units and regions, while each segment will report through the new operating structure, according to the October 7 release from Boston Scientific. For investors, the change matters because the company is moving from a broad operating model to three named reporting units, making future performance comparisons more specific.

Results date sets the next test

Boston Scientific is scheduled to release third-quarter 2026 results on October 28, 2026, according to the company calendar carried by MarketScreener. The company had previously set third-quarter adjusted earnings per share guidance at USD 0.80 to USD 0.82, while full-year adjusted earnings per share guidance stood at USD 3.28 to USD 3.32, according to MarketBeat. The October report will therefore test both the operating reset and the company guidance.

Boston Scientific stock stays near its yearly low

The Lang & Schwarz quote stood at EUR 37.72 on October 9, 2026 at 3:43 p.m. CEST, up 0.67 percent versus the EUR 37.47 prior close at Lang & Schwarz. The finance quote for the NYSE listing showed USD 42.41 at 9:55 a.m. EDT on October 9, 2026, with a 52-week range of USD 41.38 to USD 105.65 and market capitalization of USD 63.0 billion.

The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.